| Literature DB >> 33547950 |
Branka Powter1, Sarah A Jeffreys2,3, Heena Sareen2,4, Adam Cooper2,3,5, Daniel Brungs2,6, Joseph Po2, Tara Roberts3,4, Eng-Siew Koh4,5, Kieran F Scott2,3, Mila Sajinovic2, Joey Y Vessey5, Paul de Souza2,3,4,5,6, Therese M Becker2,3,4.
Abstract
The TERT promoter (pTERT) mutations, C228T and C250T, play a significant role in malignant transformation by telomerase activation, oncogenesis and immortalisation of cells. C228T and C250T are emerging as important biomarkers in many cancers including glioblastoma multiforme (GBM), where the prevalence of these mutations is as high as 80%. Additionally, the rs2853669 single nucleotide polymorphism (SNP) may cooperate with these pTERT mutations in modulating progression and overall survival in GBM. Using liquid biopsies, pTERT mutations, C228T and C250T, and other clinically relevant biomarkers can be easily detected with high precision and sensitivity, facilitating longitudinal analysis throughout therapy and aid in cancer patient management.In this review, we explore the potential for pTERT mutation analysis, via liquid biopsy, for its potential use in personalised cancer therapy. We evaluate the relationship between pTERT mutations and other biomarkers as well as their potential clinical utility in early detection, prognostication, monitoring of cancer progress, with the main focus being on brain cancer.Entities:
Keywords: Biomarker; Glioma; Liquid biopsy; TERT promoter mutation; ctDNA
Mesh：
Substances：
Year: 2021 PMID： 33547950 PMCID： PMC7954705 DOI： 10.1007/s00432-021-03536-3
Source DB: PubMed Journal: J Cancer Res Clin Oncol ISSN： 0171-5216 Impact factor: 4.553